Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
National Institute of Mental Health (NIMH)
STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in
outpatient settings. The primary purpose of this research study is to determine which
treatments work best if the first treatment with medication does not produce an acceptable
response. Participants will first receive citalopram, an SSRI medication; if symptoms remain
after 8-12 weeks of treatment, up to four other levels of treatment will be offered,
including cognitive therapy and other medications. There are no placebo treatments. Some
patients may require a combination of two or more treatments to obtain full benefit.
Participation could last from 15 to 27 months and involve up to 30 clinic visits.
Participants will be interviewed by telephone throughout the study about their symptoms,
daily functioning, treatment side effects, use of the health care system, and satisfaction
with treatment. There will be a one-year follow up for participants once their depression has
been successfully treated
Buspirone in Reducing Shortness of Breath in Patients With Cancer
National Cancer Institute (NCI)
Phase 2/Phase 3
RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients
with cancer who are undergoing chemotherapy.
PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing
shortness of breath in patients who are undergoing chemotherapy for cancer.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.